课题基金 / 基金详情

PHASE I/II TRIAL OF NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS

PHASE I/II TRIAL OF NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS
诺龙癸酸酯在患有 HIV 相关体重减轻的女性中进行的 I/II 期试验
批准号：
6303765
负责人：
Judith S. Currier
金额：
$3.56万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6303765
关键词：
AIDS AIDS therapy HIV infections androgen analog clinical research clinical trials drug screening /evaluation female hormone therapy human subject human therapy evaluation pharmacokinetics weight control agent weight loss

项目摘要

项目成果

Judith S. Currier的其他基金

相似基金

相关文献

中文摘要
翻译
本研究的目的是确定用癸醇诺龙治疗是否可以增加无意中与hiv相关的体重减轻的妇女的瘦体重。在过去的12个月里，非自愿体重下降超过5%的hiv感染妇女将被随机分配接受癸酸诺龙或安慰剂治疗12周。所有完成前12周研究的参与者将有资格在随后的12周内接受开放标签诺龙。
英文摘要
The purpose of this study is to determine whether therapy with nandrolone decanote can increase lean body mass in women wiht unintentional HIV-associated weight loss. HIV-infected women wiht involuntary wight loss >5% over the precedi 12 months will be randomly assigned to receive nandrolone decanoate or placebo for 12 weeks. All participants who complete the first 12 weeks of study will be eligible to receive open-label nandrolone for the subsequent 12 weeks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
UCLA-CDU CFAR
海外基金